Dernières nouvelles pour Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma PLC

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>), noting the company&#8217;s catalyst rich one to two years.
The M&amp;A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36413624/cytokinetics-drug-potential-analyst-suggests-key-role-of-established-pharma-for-pot" target="_blank" rel="noreferrer noopener">trial data of&nbsp;aficamten</a> in December 2023. However, last year,&nbsp;Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) decided to step back from pursuing <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36616494/cytokinetics-heart-drug-is-a-multi-billion-dollar-opportunity-by-2032-despite-novar" target="_blank" rel="noreferrer noopener">the&nbsp;Cytokinetics deal</a>.
Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) also all popped up as potential suitors, though the stock faded from there as a deal never materialized.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/09/40778617/cytokinetics-sets-stage-for-mid-stage-study-for-heart-failure-drug-after-encouraging-data-from-ph" target="_blank" rel="noreferrer noopener">Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study</a>
Cytokinetics has fallen out of favor with investors after a turbulent start to 2024, marked by a controversial Royalty Pharma Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) deal and no <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38992589/heart-disease-focused-cytokinetics-operations-are-on-track-despite-acquisition-unce" target="_blank" rel="noreferrer noopener">mergers or acquisitions</a>.
Investors poorly received the structure of the Royalty Pharma deal at the time, and it continues to be a concern for many even today.
Stifel has initiated coverage with a Buy rating and a <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast of $80</a>. However, the outlook appears promising, with its valuation adjusted and several catalysts expected over the next 12+ months.
Stifel analyst James Condulis writes Cytokinetics&#8217; aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy (oHCM) market.
As the rollout of Bristol Myers Squibb Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Camzyos mavacamten continues, some concerns remain about its potential in treating obstructive hypertrophic cardiomyopathy (oHCM).
While the initial launch is not seen as a negative sign for mavacamten&#8217;s potential, its Risk Evaluation and Mitigation Strategy (REMS) is a barrier to fully unlocking the market.
Cytokinetics appears well-positioned to capitalize on Bristol Myers&#8217; groundwork with its second-to-market drug, aficamten, which is expected to have a best-in-class profile. There is a strong case for aficamten to secure a differentiated REMS, potentially including six-month echocardiograms (Q6M echos) as a standard.
Under conservative assumptions, aficamten could drive the U.S. oHCM market to approximately $3 billion.
Looking ahead to 2025 and 2026, Phase 3 nHCM data and early findings for HFpEF could present new opportunities. Although mergers and acquisitions are not a key focus, potential strategic interest could bring unexpected benefits.
Price Action: CYTK stock is up 3.45% at $47.40 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43131221/halliburton-faces-mixed-q4-with-north-american-weakness-but-global-gains-and-cash-flow-bolster-optimism" target="_blank" rel="noreferrer noopener">Halliburton Faces Mixed Q4 With North American Weakness, But Global Gains And Cash Flow Bolster Optimism</a></li>
</ul>

Analyst Color

Biotech

News

Health Care

Price Target

Initiation

Analyst Ratings

Movers

Trading Ideas

General

AMGN

CYTK

RPRX

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) stock gained 27.97% last week after the company <a href="https://www.benzinga.com//node/42912519" target="_blank" rel="noreferrer noopener">reported better-than-expected</a> first-quarter financial results.</li>
<li>Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) stock jumped 25.80% after the company announced an agreement to acquire Calpine Corp., an electricity generation company, in a cash and stock <a href="https://www.benzinga.com//node/42916941" target="_blank" rel="noreferrer noopener">deal valued at $16.4 billion</a>.</li>
<li>FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) shares escalated by 20.48%.</li>
<li>TD SYNNEX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) stock was up 15.05% after the company reported better-than-expected <a href="https://www.benzinga.com//node/42915528" target="_blank" rel="noreferrer noopener">fourth-quarter financial results</a>.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) shares grew 14.59% after the company announced a partnership with NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Continental AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CTTAF#OTC">CTTAF</a>) to scale driverless trucks using NVIDIA's <a href="https://www.benzinga.com//node/42841305" target="_blank" rel="noreferrer noopener">next-gen DRIVE Thor SoC</a>.</li>
<li>Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) shares are up 14.35% after the company announced it <a href="https://www.benzinga.com//node/42902266" target="_blank" rel="noreferrer noopener">increased its quarterly dividend</a>.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) shares rose 13.75%. The company announced an expansion of its collaboration with Pure Storage to develop high-capacity, energy-efficient <a href="https://www.benzinga.com//node/42853369" target="_blank" rel="noreferrer noopener">solutions using Micron G9 QLC NAND</a>.</li>
<li>Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) stock upped 13.34% after the company reported better-than-expected<a href="https://www.benzinga.com//node/42912208" target="_blank" rel="noreferrer noopener"> results and issued 2025 guidance</a>.</li>
<li>Intra-Cellular Therapies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) stock gained 12.62%, entering into a settlement agreement with Sandoz and resolving a patent litigation related to CAPLYTA Patent.</li>
<li>United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) surged 12.24% in sympathy with Delta Air Lines, which rose after reporting strong <a href="https://www.benzinga.com//node/42919651" target="_blank" rel="noreferrer noopener">fourth-quarter financial results</a>.</li>
</ol>
Photo by VanderWolf via Shutterstock

Large Cap

CTTAF

FTAI

ITCI

NVDA

SNAP

Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?

U.S. stocks were lower, with the Dow Jones index falling over 700 points on Friday.
Shares of TD Synnex Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) rose sharply in today's session after the company reported <a href="https://www.benzinga.com/25/01/42915528/td-synnex-shares-delivers-earnings-beat-and-boosts-dividend-by-10">better-than-expected quarterly financial results.</a>
Quarterly revenue of $15.85 billion, up 10% Y/Y, exceeded the analyst view of $15.22 billion. The Fremont, California-based company reported an adjusted EPS of $3.09, beating the street view of $3.05.
TD Synnex shares jumped 5.5% to $128.76 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Microvast Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) shares jumped 37.3% to $2.57 after the company announced a developments in its True All-Solid-State Battery technology.</li>
<li>Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) gained 23.6% to $11.40 after the company reported better-than-expected first-quarter financial results.</li>
<li>Savers Value Village Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>) surged 13.5% to $10.63 after the company reported preliminary fourth quarter and full year net sales.</li>
<li>Oculis Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCS#NASDAQ">OCS</a>) gained 13.1% to $21.14.</li>
<li>Sasol Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) gained 13.1% to $4.99.</li>
<li>Pacira Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) climbed 12.1% to $20.83 after the company reported a preliminary year-over-year increase in FY25 revenue.</li>
<li>Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) gained 10.6% to $28.97 after the company announced it increased its quarterly dividend.</li>
<li>Merus NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) gained 9.8% to $46.35.</li>
<li>Teekay Tankers Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNK#NYSE">TNK</a>) rose 8.1% to $45.56.</li>
<li>Talos Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) gained 6.2% to $10.58.</li>
<li>TD Synnex Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) rose 5.5% to $128.76 after the company reported better-than-expected quarterly financial results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42912948/top-3-materials-stocks-that-are-set-to-fly-this-month">Top 3 Materials Stocks That Are Set To Fly This Month</a></li>
</ul>

Intraday Update

Markets

MRUS

MVST

PCRX

TALO

TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday

WIIM

Royalty Pharma shares are trading higher after the company announced it increased its quarterly dividend.

Royalty Pharma Says It Has Agreed To Acquire Its External Manager, Rp Management, Which Will Generate Cash Savings Of Greater Than $100M In 2026 And Greater Than $175M In 2030; Company Has Approved A New $3B Share Repurchase Program

Royalty Pharma board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company's quarterly dividend over the previous quarter's dividend.
The dividend will be paid on March 10, 2025 to shareholders of record at the close of business on February 21, 2025.

Dividends

Reported Earlier, Royalty Pharma Increases Quarterly Dividend By 5% To $0.22/Share, Payable March 10

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he likes Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>).
According to a CNBC report, Walmart started providing body cameras to some of its store-level employees across the U.S. as part of a pilot<a href="https://www.benzinga.com/general/psychology/24/12/42537321/walmart-begins-program-that-has-employees-wear-bodycams-for-safety"> program testing the technology</a>.
Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) is a &#8220;disappointing&#8221; stock, Cramer said. &#8220;I want you to stick with it, I would not get rid of the stock here, it's too good a company.&#8221;
On Nov. 6, Royalty Pharma reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of 93 cents per share. The company reported quarterly sales of $565.00 million which missed the analyst consensus estimate of $696.10 million.
Cramer said he doesn't want to own Magna International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>). &#8220;The autos are the worst place to be,&#8221; he noted.
On Dec. 16, Wells Fargo analyst Colin Langan maintained Magna International with an Equal-Weight rating and lowered the price target from $46 to $44.
The &#8220;Mad Money&#8221; host recommended buying M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>), adding that it is a &#8220;very, very good&#8221; company.
M&amp;T Bank will announce its fourth quarter and full-year 2024 earnings results before the market opens on Thursday, Jan. 16, 2025. Analysts expect the company to report quarterly earnings at $3.74 per share on revenue of $2.34 billion.
Price Action:
<ul>
<li>Walmart shares fell 0.2% to settle at $93.40 on Thursday.</li>
<li>Royalty Pharma shares fell 0.8% to close at $24.28 during the session.</li>
<li>Magna International shares fell 1.6% to settle at $41.28 on Thursday.</li>
<li>M&amp;T Bank shares fell 0.4% to $185.42 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42582254/top-3-consumer-stocks-you-may-want-to-dump-this-quarter">Top 3 Consumer Stocks You May Want To Dump This Quarter</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Media

Jim Cramer Likes Walmart, Recommends Buying This 'Very, Very Good' Financial Stock

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>)</h3>
<ul>
<li>Dividend Yield: 3.05%</li>
<li>Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $60 to $40 on Oct. 25. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Overweight rating and raised the price target from $48 to $51 on July 11. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Nov. 4, Royalty Pharma and Syndax Pharmaceuticals entered into $350 million royalty funding agreement for Niktimvo.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">atest RPRX news. </a></li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/21cac52e-a5a5-4623-954e-111f57f53a6d" alt="" style="width:638px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 3.13%</li>
<li>Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $180 to $185 on Oct. 16. This analyst has an accuracy rate of 77%.</li>
<li>Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and increased the price target from $163 to $166 on Oct. 16. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On Oct. 28, Johnson &amp; Johnson announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn's disease.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"> latest JNJ news.</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/572ca32b-5a3e-4fc3-b873-df0527702e1f" alt="" style="width:659px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)</h3>
<ul>
<li>Dividend Yield: 3.12%</li>
<li>Truist Securities analyst Richard Newitter maintained a Hold rating and raised the price target from $90 to $93 on Oct. 14. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Joanne Wuensch maintained a Neutral rating and increased the price target from $85 to $92 on Oct. 1. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Medtronic will report financial results for its second quarter of fiscal year 2025 on Tuesday, Nov. 19.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">trend in MDT stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png" alt="" class="wp-image-632327" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-768x713.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a>

Pre-Market Outlook

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.93 by 11.83 percent. The company reported quarterly sales of $565.00 million which missed the analyst consensus estimate of $696.10 million by 18.83 percent. This is a 5.41 percent increase over sales of $536.00 million the same period last year.

Earnings

Earnings Beats

Royalty Pharma Q3 2024 Adj EPS $1.04 Beats $0.93 Estimate

Guidance

Royalty Pharma Raises Full Year 2024 Guidance For Portfolio Receipts From $2.70B - $2.775B To $2.75B - $2.80B

Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) reported quarterly sales of $565.00 million which missed the analyst consensus estimate of $696.10 million by 18.83 percent. This is a 5.41 percent increase over sales of $536.00 million the same period last year.

Earnings Misses

Royalty Pharma Q3 Sales $565.00M May Not Be Comparable To $696.10M Estimate

Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-06. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Royalty Pharma to report an earnings per share (EPS) of $0.93.
Investors in Royalty Pharma are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.03, leading to a 0.42% increase in the share price on the subsequent day.
Here's a look at Royalty Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.99</td>
<td>0.99</td>
<td>0.99</td>
<td>0.77</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.96</td>
<td>0.98</td>
<td>1.15</td>
<td>0.79</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730815375_0.png" alt="eps graph" />
<h3>Insights Shared by Analysts on Royalty Pharma</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Royalty Pharma.
With 2 analyst ratings, Royalty Pharma has a consensus rating of Buy. The average one-year price target is $45.5, indicating a potential 67.28% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Intra-Cellular Therapies, Jazz Pharmaceuticals and Elanco Animal Health, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Intra-Cellular Therapies received a Outperform consensus from analysts, with an average 1-year price target of $100.93, implying a potential 271.07% upside.</li>
<li>As per analysts' assessments, Jazz Pharmaceuticals is favoring an Outperform trajectory, with an average 1-year price target of $180.2, suggesting a potential 562.5% upside.</li>
<li>Elanco Animal Health is maintaining an Outperform status according to analysts, with an average 1-year price target of $19.0, indicating a potential 30.15% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
Within the peer analysis summary, vital metrics for Intra-Cellular Therapies, Jazz Pharmaceuticals and Elanco Animal Health are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catalent</td>
<td>Neutral</td>
<td>23.32%</td>
<td>$384M</td>
<td>0.64%</td>
</tr>
<tr>
<td>Intra-Cellular Therapies</td>
<td>Outperform</td>
<td>39.23%</td>
<td>$159.85M</td>
<td>-2.30%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals</td>
<td>Outperform</td>
<td>6.95%</td>
<td>$913.92M</td>
<td>4.52%</td>
</tr>
<tr>
<td>Elanco Animal Health</td>
<td>Outperform</td>
<td>12.02%</td>
<td>$689M</td>
<td>-0.83%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Royalty Pharma ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
<h3>About Royalty Pharma</h3>
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson &amp; Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
<h3>Royalty Pharma: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Royalty Pharma's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -0.17%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Royalty Pharma's net margin excels beyond industry benchmarks, reaching 18.99%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.57%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Royalty Pharma's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.6%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.17.
<a href="https://www.benzinga.com/quote/RPRX/earnings">To track all earnings releases for Royalty Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Royalty Pharma's Quarterly Earnings

SNDX

Royalty Pharma Enters $350M Royalty Funding Agreement With Syndax Pharmaceuticals To Support Launches And Development Of Niktimvo And Revumenib, Boosting Proforma Cash To Nearly $800M

Citigroup analyst Andrew Baum maintains Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) with a Buy and lowers the price target from $60 to $40.

Citigroup Maintains Buy on Royalty Pharma, Lowers Price Target to $40

Royalty Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NYSE">RPRX</a>) short percent of float has fallen 3.24% since its last report. The company recently reported that it has 14.19 million shares sold short, which is 3.29% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Royalty Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728413113_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Royalty Pharma has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Royalty Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Royalty Pharma's peer group average for short interest as a percentage of float is 4.51%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Royalty Pharma's Recent Short Interest

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$65.0K</td>
<td>37.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>814</td>
<td>482</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$130.00</td>
<td>$25.3K</td>
<td>972</td>
<td>303</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$67.50</td>
<td>$196.0K</td>
<td>7</td>
<td>201</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$62.50</td>
<td>$90.0K</td>
<td>1.0K</td>
<td>200</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$128.00</td>
<td>$32.6K</td>
<td>6</td>
<td>200</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$105.3K</td>
<td>561</td>
<td>174</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$155.00</td>
<td>$55.5K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$380.00</td>
<td>$98.7K</td>
<td>10</td>
<td>57</td>
</tr>
<tr>
<td>RPRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$50.2K</td>
<td>43</td>
<td>54</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 485 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $65.0K, with a price of $325.0 per contract. There were 37533 open contracts at this strike prior to today, and today 2165 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bullish sentiment. It expires in 9 day(s) on September 27, 2024. Parties traded 104 contract(s) at a $70.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $26.2K, with a price of $252.0 per contract. There were 814 open contracts at this strike prior to today, and today 482 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with bullish sentiment. It expires in 30 day(s) on October 18, 2024. Parties traded 59 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $430.0 per contract. There were 972 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we notice a put option trade that happens to be neutral, expiring in 485 day(s) on January 16, 2026. This event was a transfer of 200 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $196.0K, with a price of $980.0 per contract. There were 7 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option trade that happens to be bullish, expiring in 121 day(s) on January 17, 2025. This event was a transfer of 200 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $90.0K, with a price of $450.0 per contract. There were 1039 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with bearish sentiment. It expires in 2 day(s) on September 20, 2024. Parties traded 102 contract(s) at a $128.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $320.0 per contract. There were 6 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 121 day(s) on January 17, 2025. Parties traded 70 contract(s) at a $315.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $105.3K, with a price of $1505.0 per contract. There were 561 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option trade with bullish sentiment. It expires in 211 day(s) on April 17, 2025. Parties traded 150 contract(s) at a $155.00 strike. The total cost received by the writing party (or parties) was $55.5K, with a price of $370.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 275 day(s) on June 20, 2025. This event was a transfer of 30 contract(s) at a $380.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $98.7K, with a price of $3290.0 per contract. There were 10 open contracts at this strike prior to today, and today 57 contract(s) were bought and sold. 
• For RPRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>), we notice a call option trade that happens to be bullish, expiring in 211 day(s) on April 17, 2025. This event was a transfer of 54 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 43 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALGN

EXAS

ILMN

MRNA

SRPT

10 Health Care Stocks With Whale Alerts In Today's Session

Tuesday, Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) reported second-quarter sales of $38.76 million (35.9 million euros), <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">missing the consensus of $92.7 million</a>, down from 47.4 million euros reported a year ago.
Results in the quarter were primarily impacted by a negative adjustment to prior periods' estimates and assumptions for sales deductions of 27.1 million euros, where 19.5 million euros and 7.6 million euros were attributable to the three months ended&nbsp;March 31, 2024, and periods before <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40697101/ascendis-pharma-reports-second-quarter-2024-financial-results" rel="noreferrer noopener">January 1, 2024, respectively</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40316248/ascendis-hypoparathyroidism-drug-scores-fda-approval-as-first-and-only-treatment-replacing-takeda" rel="noreferrer noopener">Ascendis&#8217; Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda&#8217;s Drug Discontinued Due To Supply Issues</a>.
The company reported an EPS loss of $(2.06) or (1.91 euros), missing the consensus loss of $(1.56) and down from a loss of 2.16 euros a year ago.
Skytrofa, indicated as a once-weekly pediatric growth hormone treatment, generated revenue of 26 million euros, a 27%&nbsp;decrease&nbsp;year over year. The 134% year over year volume growth was offset by the cost associated with broader market access.
Recently approved hypoparathyroidism drug Yorvipath&#8217;s revenue totaled €5.2 million, reflecting the first full quarter of commercial launch in&nbsp;Germany&nbsp;and&nbsp;Austria&nbsp;as well as initial revenue in International Markets. Initial revenue in&nbsp;France&nbsp;is expected to start in the fourth quarter of 2024.
Guidance: Ascendis Pharma has lowered its fiscal year 2024 sales guidance for Skytrofa to 220 million euros &#8211; 240 million euros from <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g38596710/ascendis-pharma-reports-first-quarter-2024-financial-results" rel="noreferrer noopener">prior guidance of</a> 320 million euros to 340 million euros.
Concurrently, the company entered into a capped synthetic royalty funding agreement based on U.S. net sales of Yorvipath with Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>).
Under the terms of the agreement, Ascendis receives an upfront payment of $150 million in exchange for a 3% royalty on U.S. net sales of Yorvipath. The royalty payments to Royalty Pharma will cease upon reaching a multiple of 2.0x or 1.65x if Royalty Pharma receives royalties in that amount by <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40697339/royalty-pharma-and-ascendis-pharma-enter-into-150-million-royalty-funding-agreement" rel="noreferrer noopener">December 31, 2029</a>.
Price Action: ASND stock is down 15% at $114.50 during the premarket session at last check Wednesday.
Photo via Shutterstock
Read Next
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40705415/dollar-tree-q2-earnings-revenue-and-eps-miss-cuts-annual-forecasts-as-customers-feel-macro-pressure" target="_blank" rel="noreferrer noopener">Dollar Tree Q2 Earnings: Revenue And EPS Miss, Cuts Annual Forecasts As Customers Feel Macro Pressure On Spending, Stock Tumbles</a>.</li>
</ul>

ASND

Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut

Contracts

Ascendis Pharma Subsidiary Enters $150M Capped Synthetic Royalty Funding Agreement With Royalty Pharma Based On US Net Sales Of YORVIPATH

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended buying Ally Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>).
On July 17, Ally Financial posted stronger-than-expected<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39847452/ally-financial-analyst-sees-consistent-margin-expansion-ahead-q2-results-breakdown"> quarterly earnings results.</a>
Cramer said he is going to hold off from recommending Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>). &#8220;It's kind of like the long knives are out for those guys right now,&#8221; he added.
On Aug. 15, Wells Fargo analyst Michael Turrin downgraded the rating for Snowflake from Overweight to Equal-Weight and lowered the price target from $200 to $130.
When asked about Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>), he said, &#8220;I always thought there was going to be more to this stock than there has been. It's really been a bit of a bust.&#8221;
On Aug. 8, Royalty Pharma reported worse-than-expected second-quarter financial results. The company reported quarterly earnings of 96 cents per share which missed the analyst consensus estimate of 99 cents per share. The company reported quarterly sales of $537.00 million which missed the analyst consensus estimate of $628.26 million.
Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) is a &#8220;very overvalued situation, principally because of the fact that it's never made any money. But it is another play on crypto. If you like crypto, buy crypto.&#8221;
On Aug. 14, Core Scientific announced that it increased its offering of convertible senior notes from $350 million to $400 million. The company has also given initial purchasers the option to buy up to an extra $60 million in notes.
Price Action:
<ul>
<li>Snowflake shares fell 0.2% to settle at $127.05 on Thursday.</li>
<li>Royalty Pharma shares rose 2.9% to close at $27.41.</li>
<li>Core Scientific shares gained 5.2% to settle at $9.26 on Thursday.</li>
<li>Ally Financial shares gained 1.3% to close at $41.61.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40394036/jim-cramer-recommends-buying-clorox-ceo-has-done-remarkable-job">Jim Cramer Recommends Buying Clorox: &#8216;CEO Has Done Remarkable Job&#8217;</a></li>
</ul>

ALLY

Core Scientific, Inc. - Class A Common Stock

CORZ

SNOW

Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'

Goldman Sachs analyst Chris Shibutani maintains Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) with a Buy and raises the price target from $50 to $51.

Goldman Sachs Maintains Buy on Royalty Pharma, Raises Price Target to $51

Royalty pharma to buy its external manager, announces $3B share buyback

Unusual total active option classes on open include: Petroleo Brasileiro (PBR/A), Royalty Pharma (RPRX), Comerica (CMA), KE Holdings (BEKE), Pitney...

Unusually active option classes on open January 10th

Royalty Pharma ( ($RPRX) ) has provided an announcement. Royalty Pharma announced its acquisition of RP Management, LLC, aiming to simplify its cor...

Royalty Pharma's Strategic Moves and Share Buyback Plan

Dividend Champion, Contender, And Challenger Highlights: Week Of January 12

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

TD Cowen analyst Michael Nedelcovych reiterated a Buy rating on Royalty Pharma (RPRX – Research Report) today and set a price target of $42.00. Mic...

Royalty Pharma's Strategic Acquisition and Share Buyback Boosts Growth Outlook

Patient Capital Management Q4 2024 Commentary

Royalty Pharma: Key Strategic Updates To Be Priced In

Syndax Looks Tantalizing, But Looks Can Be Deceptive

Cytokinetics started at buy by Stifel, aficamten highlighted

ABBV

ALRS

AMZN

APOG

ARKG

BANF

BCPC

BEKE

BIIB

CHCO

CINF

COST

CTRE

CUBE

DJIA

DTIL

EPRT

EXPE

FBTC

FCPT

FFMR

FITB

FMAO

FNLC

FULT

FUNC

GOOG

GOOGL

GWRS

IBCP

IGMS

IIPR

INTU

INVH

KURA

LAES

LECO

MDLZ

MGRC

MPWR

MRSN

NCLH

NDSN

NWFL

PGEN

PLAY

RBCAA

REXR

RGCO

RGLD

SDRL

STAG

TFII

THFF

TOWN

TSLA

WDFC

YORW

Press Releases

Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™

Financing

Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo

Royalty Pharma Reports Third Quarter 2024 Results

Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare

Royalty Pharma to Present at Upcoming Investor Conferences

Royalty Pharma Announces Dividend Increase

Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

Comments

Royalty Pharma

Actualités

Dernières nouvelles pour Royalty Pharma (NASDAQ:RPRX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL